
Product Data Sheet

FITC anti-human CD223 (LAG-3)


Catalog # / Size:	2446540 / 100 tests 2446535 / 25 tests
Clone:	11C3C65
Isotype:	Mouse IgG1, к
Immunogen:	Human LAG-3 transfected cells.
Reactivity:	Human
Preparation:	The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC and unconjugated antibody.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
Concentration:	Lot-specific



CD3/CD28/IL-2 stimulated (three days) peripheral blood mononuclear cells were stained with CD8a Pacific Blue™ and CD223 (clone 11C3C65) FITC (top) or mouse IgG1, κ FITC isotype control (bottom).

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:	The staining of clone 11C3C65 cannot be blocked by clone 7H2C65, which is another anti-human CD223 (LAG-3) antibody.



Description: CD223, also known as LAG-3, is a 70 kD type I transmembrane glycoprotein that is involved in T-cell signaling. Similar to CD4, CD223 binds MHC class II, but with a higher affinity. CD223 negatively regulates T-cell activation. It is expressed by activated T-cells and natural killer cells (NKs), as well as regulatory T-cells. It is transiently expressed on the surface of activated T-cells in acute conditions but high expression is maintained under tolerizing conditions. CD223 deficiency results in reduced tumor growth. CD223 and PD-1 can act in synergy and reverse exhausted phenotypes, improve tumor rejection, and control viral load.
Antigen 1. Castelli C, *et al.* 2014. *Oncoimmunology*. 3(11):e967146.

,	
References:	2. Poirier N, <i>et al.</i> 2011. <i>Clin. Exp. Immunol.</i> 164:265.
	3. Juno JA, <i>et al.</i> 2015. <i>Retrovirology.</i> 12:17.

4. Casati C, *et*

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com